Zoledronic Acid Dosing Interval for Metastatic Cancer

To the Editor A noninferiority trial investigated the optimal schedule for zoledronic acid in patients with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma with at least 1 bone metastasis, demonstrating similar efficacy with less frequent administration. This finding is important because some adverse effects of bisphosphonates are related to cumulative drug exposure. Furthermore, life expectancy of these patients is increasing, and therefore they are treated for longer periods.
Source: JAMA - Category: Journals (General) Source Type: research